Riik: Iirimaa
keel: inglise
Allikas: HPRA (Health Products Regulatory Authority)
CANINE PARVOVIRUS, STRAIN NL-35-D, LIVE ATTENUATED
Pfizer Healthcare Ireland
QI07AD01
Solution for Injection
Immunological - Live Vaccine
Canine
2004-05-28
IRISH MEDICINES BOARD ACT 1995, AS AMENDED EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (NO. 2) REGULATIONS 2007 VPA: 10019/072/001 Case No: 7007027 The Irish Medicines Board in exercise of the powers conferred on it by Animal Remedies (No. 2) Regulations (S.I. No. 786 of 2007) hereby grants to: PFIZER HEALTHCARE IRELAND TRADING AS: PFIZER ANIMAL HEALTH, RINGASKIDDY, CO. CORK, IRELAND an authorisation, subject to the provisions of the said Regulations and the general conditions of the attached authorisation, in respect of the Veterinary Medicinal Product: VANGUARD CPV The particulars of which are set out in the attached Schedule. The authorisation is also subject to any special conditions as may be specified in the Schedule. The authorisation,unless revoked, shall continue in force from 30/08/2010. Signed on behalf of the Irish Medicines Board ________________ A person authorised in that behalf by the said Board. (NOTE: This authorisation replaces any previous authorisation in respect of this product which is now null and void.) IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 31/08/2010_ _CRN 7007027_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Vanguard CPV 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Quantity per 1 ml dose ACTIVE SUBSTANCE(S): Live attenuated canine Parvovirus, strain NL-35-D, low passage, minimum : 10 7.0 CCID 50 * *Cell culture infectious dose-50 For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. The liquid is slightly turbid, reddish in colour. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs from 5 weeks of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of Lugege kogu dokumenti